{
    "nct_id": "NCT05493215",
    "official_title": "A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal Tumor",
    "inclusion_criteria": "* Histologically or cytologically confirmed GIST with KIT mutation or PDGFRA mutation (non-D842V)\n* Currently receiving imatinib initiated within the last 3 months or to be started in the next 1 month\n* Prior systemic chemotherapy for other malignancy is allowed as long as it was completed within the past 6 months and there is no evidence of disease\n* Age â‰¥18 years\n* ECOG performance status of 0 or 1\n* Normal organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of PDGFRA D842V mutation\n* Known allergy to imatinib or allergic reactions to compounds of similar chemical or biologic composition to the study drug\n* Concomitant anticoagulation with oral warfarin.\n* Use of strong inhibitors or inducers of CYP3A or CYP3A4, drugs metabolized by CYP3A4 or CYP2D6\n* Uncontrolled intercurrent illness\n* Concurrent malignancy",
    "miscellaneous_criteria": ""
}